KIT and systemic mastocytosis: Similarly, worsening cytopenias were observed with the use of KIT inhibitors in advanced systemic mastocytosis, and the CRh category was introduced to the modified IWG response criteria used in the evaluation of avapritinib in advanced systemic mastocytosis [27].